Microencapsulación de Biocidas

Los productos biocidas presentan una serie de limitaciones para su uso como son: -Perfil toxicológico que limita su utilización en todos lo ámbitos. -Solubilidad que imposibilita o dificulta la utilización del agua como vehículo de elección. -Estado físico que en algunos casos complica la manipulación del biocida por el operador. -Condiciones de almacenamiento que precisan protección frente a la luz y a la temperatura. En esta memoria se plantea como solución a esta problemática, la formación de microencapsulados (complejos de inclusión) de biocidas de tres familias diferentes (nicotinoides, piretroides y carbamatos) y del sinergista butóxido de piperonilo, con ciclodextrinas (oligosacáridos cíclicos). El objetivo de esta investigación es desarrollar las herramientas adecuadas que permitan obtener un producto medioambientalmente compatible, que sirva de base para la obtención de formulaciones eficaces aplicables al control de plagas de insectos voladores, concretamente enfocado a la mosca doméstica (Musca doméstica), tanto en el interior como en el exterior de entornos urbanos y ganaderos. Una vez obtenido el microencapsulado se lleva a cabo su caracterización mediante diversas técnicas analíticas instrumentales: -Electroforesis capilar de zona (ECZ). -Estudios de solubilidad de fase mediante espectroscopía uv-vis. -Estudios calorimétricos (DSC, TG y DTA). -Resonancia Magnética Nuclear (RMN-H1 y RMN-C13). -Análisis Elemental (AE). -Microscopía Electrónica de Barrido (SEM). -Espectroscopía Infrarroja con Transformada de Fourier (FT-IR).

A short in-frame deletion in NTRK1 tyrosine kinase domain caused by a novel splice site mutation in a patient with congenital insensitivity to pain with anhidrosis

Background: Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive genetic disease characterized by the lack of reaction to noxious stimuli and anhidrosis. It is caused by mutations in the NTRK1 gene, which encodes the high affinity tyrosine kinase receptor I for Neurotrophic Growth Factor (NGF). -- Case Presentation: We present the case of a female patient diagnosed with CIPA at the age of 8 months. The patient is currently 6 years old and her psychomotor development conforms to her age (RMN, SPECT and psychological study are in the range of normality). PCR amplification of DNA, followed by direct sequencing, was used to investigate the presence of NTRK1 gene mutations. Reverse transcriptase (RT)-PCR amplification of RNA, followed by cloning and sequencing of isolated RT-PCR products was used to characterize the effect of the mutations on NTRK1 mRNA splicing. The clinical diagnosis of CIPA was confirmed by the detection of two splice-site mutations in NTRK1, revealing that the patient was a compound heterozygote at this gene. One of these alterations, c.574+1G > A, is located at the splice donor site of intron 5. We also found a second mutation, c.2206-2 A > G, not previously reported in the literature, which is located at the splice acceptor site of intron 16. Each parent was confirmed to be a carrier for one of the mutations by DNA sequencing analysis. It has been proposed that the c.574+1G > A mutation would cause exon 5 skipping during NTRK1 mRNA splicing. We could confirm this prediction and, more importantly, we provide evidence that the novel c.2206-2A > G mutation also disrupts normal NTRK1 splicing, leading to the use of an alternative splice acceptor site within exon 17. As a consequence, this mutation would result in the production of a mutant NTRK1 protein with a seven aminoacid in-frame deletion in its tyrosine kinase domain. --Conclusions: We present the first description of a CIPA-associated NTRK1 mutation causing a short interstitial deletion in the tyrosine kinase domain of the receptor. The possible phenotypical implications of this mutation are discussed.

Aldehídos en reacciones de Michael enantioselectivas catalizadas por derivados del prolinol

426 p. : graf.

Optimization of Organic-Inorganic Inter-phase in Hybrid Systems Based on Waterborne Polyurethanes and Silica Nanostructures

215 p.